Aspira Women’s Health, Inc. to Report Second Quarter 2020 Financial Results on August 13th

Rhea-AI Summary

Aspira Women's Health (Nasdaq: VRML) will release its second-quarter financial results for the period ending June 30, 2020, on August 13, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET. Aspira focuses on innovative testing solutions for women's health, emphasizing ovarian cancer risk assessment and pelvic disease diagnostics. The company highlights its FDA-cleared product portfolio, including OVA1® plus and ASPIRA GenetiX™, while also developing new offerings like OVANEX™ and EndoCheck™.

Positive

• Aspira's focus on innovative testing solutions for women's health.
• Strong emphasis on closing the ethnic disparity gap in ovarian cancer risk assessment.
• FDA-cleared products in its portfolio, including OVA1® plus and OVERA®.

Negative

• None.

AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, August 13th @ 4:30pm ET
Domestic:	201-689-8472
International:	877-407-4021
Conference ID:	13706942
Webcast:	http://public.viavid.com/index.php?id=140750

About Aspira Women’s Health Inc.
Aspira Women’s Health, Inc. (formerly known as, Vermillion Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1^® plus includes our FDA-cleared products, OVA1^® and OVERA^® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:

Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

When will Aspira Women's Health report its financial results for Q2 2020?

Aspira Women's Health will report its financial results for Q2 2020 on August 13, 2020, after market close.

What is the ticker symbol for Aspira Women's Health?

The ticker symbol for Aspira Women's Health is VRML.

What products does Aspira Women's Health offer for ovarian cancer assessment?

Aspira Women's Health offers FDA-cleared products such as OVA1® and OVERA® for ovarian cancer risk assessment.

What new products is Aspira Women's Health developing?

Aspira Women's Health is developing new products including OVANEX™ and EndoCheck™.

What time is the investor conference call scheduled for August 13, 2020?

The investor conference call is scheduled for 4:30 PM ET on August 13, 2020.